Congruence and Ono Pharma Expand Multi-Target Research Partnership with the Addition of Two New Programs
PR Newswire —
Expanded collaboration continues to leverage Congruence's proprietary computational drug discovery engine, Revenir™ to deliver Development Candidates in Neurology and Immunology Congruence to receive undisclosed upfront payment as well as R&D funding, milestones and royalties OSAKA, Japan...